AR124199A1 - Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa - Google Patents
Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasaInfo
- Publication number
- AR124199A1 AR124199A1 ARP210103440A ARP210103440A AR124199A1 AR 124199 A1 AR124199 A1 AR 124199A1 AR P210103440 A ARP210103440 A AR P210103440A AR P210103440 A ARP210103440 A AR P210103440A AR 124199 A1 AR124199 A1 AR 124199A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- compounds
- pde
- androgen receptor
- independently selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 102000001307 androgen receptors Human genes 0.000 title abstract 7
- 108010080146 androgen receptors Proteins 0.000 title abstract 7
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 229940125436 dual inhibitor Drugs 0.000 title 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 4
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 1
- 101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación proporciona compuestos inhibidores del receptor de andrógenos (AR) y de la fosfodiesterasa 5 (PDE-5) y composiciones que incluyen dichos compuestos. Los compuestos pueden proporcionar una funcionalidad dual para inhibir el AR e inhibir la PDE-5. La presente divulgación también proporciona métodos para utilizar dichos compuestos y composiciones para inhibir el AR y la PDE-5 en un sistema o muestra biológica. También se proporcionan métodos de preparación de dichos compuestos y composiciones, y precursores sintéticos de dichos compuestos. Reivindicación 1: Un compuesto de fórmula (1) o un solvato, un hidrato, un profármaco y/o un estereoisómero de este, o una sal farmacéuticamente aceptable de este, caracterizado porque: L es una porción de enlace; R¹ y R² se seleccionan de manera independiente entre -H, alquilo(C₁-C₆) opcionalmente sustituido, cicloalquilo(C₃-C₆) opcionalmente sustituido, alcoxi(C₁-C₆) opcionalmente sustituido y alquenilo(C₂-C₄) opcionalmente sustituido; cada R¹³ se selecciona entre -H, alquilo(C₁-C₆) opcionalmente sustituido y alcoxi(C₁-C₆) opcionalmente sustituido; cada R¹⁴ se selecciona de forma independiente de -H, -CN, -OH, -NH₂, -NO₂, halógeno, alquilo(C₁-C₅) opcionalmente sustituido, haloalquilo(C₁-C₅) opcionalmente sustituido, alcoxi(C₁-C₅) opcionalmente sustituido, cicloalquilo(C₃-C₆) opcionalmente sustituido y alquenilo(C₂-C₄) opcionalmente sustituido; X¹ es N o CR¹⁴; X² y X³ se seleccionan de manera independiente entre N y CR¹³; Y¹ e Y² se seleccionan de manera independiente entre N y C, donde uno entre Y¹ e Y² es N; m es 0 a 2; y n es 1 a 4. Reivindicación 42: Un método para modular el receptor de andrógenos y/o inhibir PDE-5, el método caracterizado porque comprende poner en contacto un sistema biológico que comprende el receptor de andrógenos y/o PDE-5 con una cantidad de eficaz de un compuesto o un solvato, un hidrato, un profármaco, y/o un estereoisómero de este, o una sal farmacéuticamente aceptable de este según una cualquiera de las reivindicaciones 1 a 40 o una composición farmacéutica según la reivindicación 41.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124615P | 2020-12-11 | 2020-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124199A1 true AR124199A1 (es) | 2023-02-22 |
Family
ID=81974180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103440A AR124199A1 (es) | 2020-12-11 | 2021-12-10 | Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11787812B2 (es) |
| EP (1) | EP4259634A4 (es) |
| JP (1) | JP2023552632A (es) |
| KR (1) | KR20230118137A (es) |
| CN (1) | CN116848116A (es) |
| AR (1) | AR124199A1 (es) |
| AU (1) | AU2021396593A1 (es) |
| CA (1) | CA3201054A1 (es) |
| CL (1) | CL2023001673A1 (es) |
| CO (1) | CO2023009145A2 (es) |
| CR (1) | CR20230306A (es) |
| EC (1) | ECSP23051657A (es) |
| IL (1) | IL303407A (es) |
| MX (1) | MX2023006911A (es) |
| PE (1) | PE20240248A1 (es) |
| TW (1) | TW202237615A (es) |
| WO (1) | WO2022123310A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3201054A1 (en) * | 2020-12-11 | 2022-06-16 | Yoon-Suk Lee | Novel compounds as androgen receptor and phosphodiesterase dual inhibitor |
| WO2023244059A1 (en) * | 2022-06-15 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds |
| CN115819303B (zh) * | 2022-11-15 | 2024-10-01 | 江苏睿实生物科技有限公司 | 一种化合物3-氟-4-异硫氰基-2-三氟甲基苄腈的制备方法 |
| US20250136578A1 (en) * | 2023-10-12 | 2025-05-01 | Kolm Therapeutics Inc. | Bifunctional androgen receptor compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309332C (en) * | 1997-11-12 | 2002-12-03 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| DE19827640A1 (de) | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
| KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| DE10010067A1 (de) * | 2000-03-02 | 2001-09-06 | Bayer Ag | Neue Imidazotriazinone und ihre Verwendung |
| KR100377782B1 (ko) | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
| GB0222833D0 (en) | 2002-10-02 | 2002-11-06 | Syngenta Ltd | Chemical process |
| JP2004170323A (ja) | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
| KR101782236B1 (ko) | 2005-05-13 | 2017-09-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| CN1966506A (zh) | 2005-11-17 | 2007-05-23 | 上海特化医药科技有限公司 | 吡唑并嘧啶酮衍生物及其制备方法和用途 |
| WO2008045664A2 (en) | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Heterocyclic pde4 inhibitors as antiinflammatory agents |
| KR20090087795A (ko) | 2008-02-13 | 2009-08-18 | 한양대학교 산학협력단 | 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트 |
| JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| US8524755B2 (en) | 2009-02-24 | 2013-09-03 | Medivation Prostate Therapeutics, Inc. | Specific diarylhydantoin and diarylthiohydantoin compounds |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| CN101691373B (zh) | 2009-10-21 | 2011-12-07 | 段波 | 一种治疗勃起功能障碍和早泄的药物及其制备 |
| CN102970965A (zh) | 2010-04-05 | 2013-03-13 | Sk化学公司 | 含有pde5抑制剂的减少皮肤皱纹的合成物 |
| CN102134242B (zh) | 2011-01-21 | 2013-08-28 | 浙江大德药业集团有限公司 | 一种用于治疗阳痿的快速长效的化合物 |
| DK2961741T3 (en) | 2013-03-01 | 2017-07-03 | Fund Para La Investig Medica Aplicada | Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases |
| US9969744B2 (en) * | 2014-08-04 | 2018-05-15 | Fundación La Investigación Médica Aplicada | Compounds for use in cognition improvement |
| WO2016120432A1 (en) | 2015-01-30 | 2016-08-04 | Fundación Para La Investigación Médica Aplicada | Compounds and methods for anticoagulation therapy |
| JP2018076234A (ja) | 2015-03-16 | 2018-05-17 | 大正製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| CA3201054A1 (en) * | 2020-12-11 | 2022-06-16 | Yoon-Suk Lee | Novel compounds as androgen receptor and phosphodiesterase dual inhibitor |
-
2021
- 2021-12-10 CA CA3201054A patent/CA3201054A1/en active Pending
- 2021-12-10 CR CR20230306A patent/CR20230306A/es unknown
- 2021-12-10 AR ARP210103440A patent/AR124199A1/es unknown
- 2021-12-10 CN CN202180091127.7A patent/CN116848116A/zh active Pending
- 2021-12-10 MX MX2023006911A patent/MX2023006911A/es unknown
- 2021-12-10 KR KR1020237022717A patent/KR20230118137A/ko active Pending
- 2021-12-10 WO PCT/IB2021/000856 patent/WO2022123310A1/en not_active Ceased
- 2021-12-10 PE PE2023001858A patent/PE20240248A1/es unknown
- 2021-12-10 JP JP2023535657A patent/JP2023552632A/ja active Pending
- 2021-12-10 TW TW110146422A patent/TW202237615A/zh unknown
- 2021-12-10 EP EP21902772.9A patent/EP4259634A4/en active Pending
- 2021-12-10 IL IL303407A patent/IL303407A/en unknown
- 2021-12-10 US US17/548,279 patent/US11787812B2/en active Active
- 2021-12-10 AU AU2021396593A patent/AU2021396593A1/en active Pending
-
2023
- 2023-06-09 CL CL2023001673A patent/CL2023001673A1/es unknown
- 2023-07-10 CO CONC2023/0009145A patent/CO2023009145A2/es unknown
- 2023-07-10 EC ECSENADI202351657A patent/ECSP23051657A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11787812B2 (en) | 2023-10-17 |
| EP4259634A1 (en) | 2023-10-18 |
| JP2023552632A (ja) | 2023-12-18 |
| PE20240248A1 (es) | 2024-02-19 |
| ECSP23051657A (es) | 2023-08-31 |
| CA3201054A1 (en) | 2022-06-16 |
| CR20230306A (es) | 2023-09-01 |
| AU2021396593A1 (en) | 2023-07-20 |
| CL2023001673A1 (es) | 2023-12-01 |
| TW202237615A (zh) | 2022-10-01 |
| US20220194948A1 (en) | 2022-06-23 |
| CO2023009145A2 (es) | 2023-07-21 |
| IL303407A (en) | 2023-08-01 |
| KR20230118137A (ko) | 2023-08-10 |
| CN116848116A (zh) | 2023-10-03 |
| MX2023006911A (es) | 2023-06-26 |
| EP4259634A4 (en) | 2024-11-20 |
| WO2022123310A1 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124199A1 (es) | Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa | |
| PE20241127A1 (es) | Compuestos triciclicos como inhibidores de kras | |
| ZA202102999B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| AR110038A1 (es) | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| EA200801828A2 (ru) | Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| AR122092A1 (es) | Inhibidores de diacilglicerol o-aciltransferasa 2 | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| AR109650A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CO2024012060A2 (es) | Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| PE20230235A1 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| AR103629A1 (es) | Compuestos con actividad antitumoral |